Diabetes Decline Continues On Schedule At Sanofi

"The good news is that there is no news," said Sanofi's CEO Olivier Brandicourt, commenting on the company's diabetes franchise during its 2015 annual results presentation on Feb 9. "We delivered exactly what we said we would." Sanofi managed this by offsetting worse than expected Lantus sales with a better than expected performance by its newer insulin glargine injection, Toujeo.